Leah Rush Cann, M.B.A.

Leah Rush Cann is a Biotechnology Research Analyst at Brookline and was previously a Managing Director at Oppenheimer & Co. A scientist by training, she began her career as a research scientist at Memtec Corporation before moving to Wall Street in 1992, where she spent nearly nine years as a research analyst at Oppenheimer. Ms. Cann has also served as a healthcare analyst at Boston-based asset manager Cadence Capital and as senior biotechnology analyst at Wachovia Securities. Twice recognized as an All-Star analyst by The Wall Street Journal, she is the founder of Leah Rush Cann Research and Consulting, an oncology research and consulting organization.

Ms. Cann holds a B.A. in Art History and Chemistry and an M.B.A. from Stetson University, and completed post-baccalaureate studies at the College of William and Mary and post-graduate studies at Columbia University. Outside of research, Ms. Cann is deeply engaged in the cancer research community. In 2007, she founded Hope Funds for Cancer Research, a Rhode Island-based charity where she continues to serve on the board and chairs the Executive Committee. She also serves on the Advisory Board of the RNA Institute at Beth Israel Deaconess Medical Center’s Cancer Center at Harvard University, has served on the Board of Directors of MEI Pharma and has been a trustee and committee member of International House in New York City for more than 20 years.